Cost-Effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy as first-line maintenance for patients with advanced ovarian cancer: a analysis from a Chinese healthcare perspective
{{output}}
Objective: The PAOLA-1 trial demonstrated that olaparib plus bevacizumab (OB) significantly prolonged progression-free survival (PFS) and overall survival (OS) compared to bevacizumab monotherapy (BM) as first-line maintenance th... ...
